Dana-Farber Cancer Institute: Leukemia trials

The registry lists 45 Leukemia studies with Dana-Farber Cancer Institute as lead sponsor. 9 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 21Phase 2 10Phase 3 3No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ALL Backbone in AYAsRecruitingNCT07227584Phase 2
• Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta TestingRecruitingNCT06907797Not applicable
• HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable
• Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)RecruitingNCT06469307Not applicable
• CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 1
• Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
• Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy SpecimensRecruitingNCT04968834
• A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationRecruitingNCT04024761Phase 1
• A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingNCT03219450Phase 1
• Insomnia Prevention in Children With Acute Lymphoblastic LeukemiaCompletedNCT05866887Not applicableResults posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• GVAX vs. Placebo for MDS/AML After Allo HSCTTerminatedNCT01773395Phase 2Results posted
• Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01066663Phase 1/2Results posted
• Deferoxamine for Iron Overload Before Allogeneic Stem Cell TransplantationTerminatedNCT00658411Not applicableResults posted
• 05-001: Treatment of Acute Lymphoblastic Leukemia in ChildrenCompletedNCT00400946Phase 3Results posted
• Pilot of a Trial Enrollment Diversity DashboardCompletedNCT06795139Not applicable
• Feasibility Pilot Exploring Variability in Biomarkers and PROs in AMLCompletedNCT04908852
• Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsActive, not recruitingNCT03974217Phase 1
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
• Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALLActive, not recruitingNCT03319901Phase 1/2
• ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLActive, not recruitingNCT02787369Phase 1
• Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALLCompletedNCT01523977Phase 1
• Observational Study of Iron Overload in Stem Cell TransplantationCompletedNCT00954720
• Rapamycin in Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00874562Phase 1
• Collection and Banking of Leukemia Cells MDS/AMLCompletedNCT00809367Not applicable
• Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
• Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLTerminatedNCT00543114Phase 1
• Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationCompletedNCT00442130Phase 1
• Natural History Study of Patients With Chronic Myelogenous LeukemiaCompletedNCT00429910
• Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine GenerationCompletedNCT00428233Phase 1
• GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid MalignanciesCompletedNCT00426205Not applicable
• Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell TransplantCompletedNCT00376480Phase 1
• Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLCompletedNCT00330252Phase 1
• Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00301093Phase 1
• Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory LeukemiaCompletedNCT00251368Phase 1
• Treatment of Acute Lymphoblastic Leukemia in ChildrenCompletedNCT00165178Phase 3
• Treatment of Childhood Acute Lymphoblastic LeukemiaTerminatedNCT00165087Phase 3
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
• A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
• High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
• Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
• Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2
• Vaccine Therapy in Treating Patients With Acute Lymphoblastic LeukemiaTerminatedNCT00020670Early Phase 1
• Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous TherapyCompletedNCT00005988Phase 1